GELS Gelteq Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1920092 · Reporting currency AUD · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-06-30 · AUD | FY20242024-06-30 · AUD | FY20232023-06-30 · AUD |
|---|---|---|---|
| Income statement | |||
| Revenue | 165,645 | — | 79,843 |
| Cost of revenue | 115,397 | — | — |
| Gross profit | 50,248 | — | — |
| R&D expense | 628,606 | 276,057 | 665,035 |
| Operating income | -5.50M | -2.95M | -3.10M |
| Interest expense | 1.92M | 599,494 | 403,107 |
| Pretax income | -6.65M | -3.55M | -3.51M |
| Net income | -$6.65MUSD | -3.55M | -3.51M |
| EBITDA | -4.27M | -1.73M | -1.88M |
| EPS (basic) | -0.72 | -0.44 | -0.44 |
| EPS (diluted) | -0.72 | -0.44 | -0.44 |
| Balance sheet | |||
| Cash & equivalents | 344,648 | 24,522 | 399,224 |
| Receivables | 459,724 | 183,005 | 345,291 |
| Inventory | — | — | 95,201 |
| Current assets | 1.51M | 303,227 | 990,974 |
| PP&E, netmay include right-of-use assets (IFRS) | 15,907 | 16,642 | — |
| Intangibles | 19.86M | 20.44M | 21.49M |
| Total assets | 21.48M | 20.76M | 22.49M |
| Current liabilities | 5.63M | 3.87M | 1.36M |
| Short-term debt | 4.20M | 2.08M | 5,086 |
| Long-term debt | 13,550 | 1.76M | 2.47M |
| Total debt | 4.22M | 3.84M | 2.48M |
| Total liabilities | 5.67M | 5.65M | 3.84M |
| Shareholders' equity | 15.80M | 15.11M | 18.66M |
| Net debt | 3.87M | 3.82M | 2.08M |
| Cash flow statement | |||
| Operating cash flow | -5.52M | -1.07M | -1.77M |
| Capital expenditure | 3,117 | 3,149 | 34,503 |
| Free cash flow | -5.52M | -1.07M | -1.80M |
| Investing cash flow | -736,839 | -148,170 | -75,931 |
| Financing cash flow | 6.45M | 843,939 | 2.03M |
| Depreciation & amortization | 1.22M | 1.21M | 1.23M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.